Last reviewed · How we verify
Methylprednisolone/prednisolone
Methylprednisolone and prednisolone are corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Methylprednisolone and prednisolone are corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, vasculitis), Allergic reactions and asthma exacerbations, Adrenal insufficiency.
At a glance
| Generic name | Methylprednisolone/prednisolone |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
These synthetic glucocorticoids bind to intracellular glucocorticoid receptors, translocate to the nucleus, and modulate gene expression to decrease production of inflammatory mediators (cytokines, chemokines, adhesion molecules). They suppress T-cell and B-cell function, reduce vascular permeability, and stabilize lysosomal membranes, resulting in broad anti-inflammatory and immunosuppressive effects across multiple organ systems.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, vasculitis)
- Allergic reactions and asthma exacerbations
- Adrenal insufficiency
- Cerebral edema
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis
- Immunosuppression/increased infection risk
- Insomnia
- Mood changes (anxiety, depression)
- Gastrointestinal upset
- Cushingoid features (with chronic use)
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylprednisolone/prednisolone CI brief — competitive landscape report
- Methylprednisolone/prednisolone updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI